HERON THERAPEUTICS INC DE

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

HRTX$0.37+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Deficit

	Common Stock
Shares · Amount · Additional Paid-InCapital · Accumulated Other ComprehensiveIncome (Loss) · Accumulated Deficit · Total Stockholders’Deficit
Balance as of December 31, 2024	152,128	$1,521	$1,884,409	$13		$(1,919,594)	$(33,651)
Issuance of common stock under equity incentive plan	299	3	61	—		—	64
Stock-based compensation expense	—	—	2,511	—		—	2,511
Net income	—	—	—	—		2,635	2,635
Net unrealized loss on short-term investments	—	—	—	(12)		—	(12)
Comprehensive income					2,623
Balance as of March 31, 2025 (unaudited)	152,427	1,524	1,886,981	1		(1,916,959)	(28,453)

	Common Stock
Shares · Amount · Additional Paid-InCapital · Accumulated Other ComprehensiveIncome (Loss) · AccumulatedDeficit · Total Stockholders’Deficit
Balance as of December 31, 2023	150,285	$1,503	$1,870,525	$13		$(1,906,014)	$(33,973)
Issuance of common stock under equity incentive plan	93	1	10	—		—	11
Stock-based compensation expense	—	—	3,375	—		—	3,375
Net loss	—	—	—	—		(3,160)	(3,160)
Net unrealized losses on short-term investments	—	—	—	(19)		—	(19)
Comprehensive loss					(3,179)
Balance as of March 31, 2024 (unaudited)	150,378	1,504	1,873,910	(6)		(1,909,174)	(33,766)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.